REG-Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
Oculis will host an in-person and virtual R&D Day at St. Regis New York on December 8, 2026, at 10:00 EST, featuring management and seven academic key opinion leaders. The event will spotlight the PREDICT-1 registrational trial of Licaminlimab in TNFR1-mediated dry eye disease, with topline results anticipated around year-end, and the Privosegtor PIONEER program in optic neuritis plus a planned first neurological indication in acute MS relapse, with IND clearance anticipated this quarter.
Key figures
- Ind privosegtor ms
- IND clearance anticipated this quarter
- Topline data timing
- Licaminlimab PREDICT-1 topline results anticipated around year-end 2026
- Tnfr1 mediated ded us patients
- 1.5+ million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.